Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

The use of Fionet technology for external quality control of malaria rapid diagnostic tests and monitoring health workers' performance in rural military health facilities in Tanzania.

Kalinga AK, Ishengoma DS, Kavishe R, Temu L, Mswanya C, Mwanziva C, Mgina EJ, Chiduo S, Mahikwano L, Mgata S, Anova L, Amoo G, Wurapa E, Vesely B, Kamau E, Hickman M, Waters N, Kreishman-Deitrick M, Paris R, Ohrt C.

PLoS One. 2018 Dec 27;13(12):e0208583. doi: 10.1371/journal.pone.0208583. eCollection 2018.

2.

Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.

Warrasak S, Euswas A, Fukuda MM, Ittiverakul M, Miller RS, Krudsood S, Ohrt C.

Int Ophthalmol. 2019 Aug;39(8):1767-1782. doi: 10.1007/s10792-018-1003-2. Epub 2018 Sep 29.

PMID:
30269312
3.

Comparison of visual and automated Deki Reader interpretation of malaria rapid diagnostic tests in rural Tanzanian military health facilities.

Kalinga AK, Mwanziva C, Chiduo S, Mswanya C, Ishengoma DI, Francis F, Temu L, Mahikwano L, Mgata S, Amoo G, Anova L, Wurrapa E, Zwingerman N, Ferro S, Bhat G, Fine I, Vesely B, Waters N, Kreishman-Deitrick M, Hickman M, Paris R, Kamau E, Ohrt C, Kavishe RA.

Malar J. 2018 May 29;17(1):214. doi: 10.1186/s12936-018-2363-9.

4.

A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria.

Fukuda MM, Krudsood S, Mohamed K, Green JA, Warrasak S, Noedl H, Euswas A, Ittiverakul M, Buathong N, Sriwichai S, Miller RS, Ohrt C.

PLoS One. 2017 Nov 9;12(11):e0187376. doi: 10.1371/journal.pone.0187376. eCollection 2017.

5.

Field evaluation of diagnostic performance of malaria rapid diagnostic tests in western Kenya.

Wanja EW, Kuya N, Moranga C, Hickman M, Johnson JD, Moseti C, Anova L, Ogutu B, Ohrt C.

Malar J. 2016 Sep 7;15:456. doi: 10.1186/s12936-016-1508-y.

6.

Information systems to support surveillance for malaria elimination.

Ohrt C, Roberts KW, Sturrock HJW, Wegbreit J, Lee BY, Gosling RD.

Am J Trop Med Hyg. 2015 Jul;93(1):145-152. doi: 10.4269/ajtmh.14-0257. Epub 2015 May 26. Review.

7.

Tackling imported malaria: an elimination endgame.

Sturrock HJW, Roberts KW, Wegbreit J, Ohrt C, Gosling RD.

Am J Trop Med Hyg. 2015 Jul;93(1):139-144. doi: 10.4269/ajtmh.14-0256. Epub 2015 May 26. Review.

8.

Efficacy of intravenous methylene blue, intravenous artesunate, and their combination in preclinical models of malaria.

Ohrt C, Li Q, Obaldia N, Im-Erbsin R, Xie L, Berman J.

Malar J. 2014 Oct 21;13:415. doi: 10.1186/1475-2875-13-415.

9.

Anti-relapse activity of mirincamycin in the Plasmodium cynomolgi sporozoite-infected Rhesus monkey model.

Fracisco S, Teja-isavadharm P, Gettayacamin M, Berman J, Li Q, Melendez V, Saunders D, Xie L, Ohrt C.

Malar J. 2014 Oct 17;13:409. doi: 10.1186/1475-2875-13-409.

10.

Pharmacokinetics and pharmacodynamics of (+)-primaquine and (-)-primaquine enantiomers in rhesus macaques (Macaca mulatta).

Saunders D, Vanachayangkul P, Imerbsin R, Khemawoot P, Siripokasupkul R, Tekwani BL, Sampath A, Nanayakkara NP, Ohrt C, Lanteri C, Gettyacamin M, Teja-Isavadharm P, Walker L.

Antimicrob Agents Chemother. 2014 Dec;58(12):7283-91. doi: 10.1128/AAC.02576-13. Epub 2014 Sep 29.

11.

Scalable preparation and differential pharmacologic and toxicologic profiles of primaquine enantiomers.

Nanayakkara NP, Tekwani BL, Herath HM, Sahu R, Gettayacamin M, Tungtaeng A, van Gessel Y, Baresel P, Wickham KS, Bartlett MS, Fronczek FR, Melendez V, Ohrt C, Reichard GA, McChesney JD, Rochford R, Walker LA.

Antimicrob Agents Chemother. 2014 Aug;58(8):4737-44. doi: 10.1128/AAC.02674-13. Epub 2014 Jun 9.

12.

Causal prophylactic efficacy of primaquine, tafenoquine, and atovaquone-proguanil against Plasmodium cynomolgi in a rhesus monkey model.

DiTusa C, Kozar MP, Pybus B, Sousa J, Berman J, Gettayacamin M, Im-erbsin R, Tungtaeng A, Ohrt C.

J Parasitol. 2014 Oct;100(5):671-3. doi: 10.1645/13-480.1. Epub 2014 Apr 29.

PMID:
24780070
13.

Humanized mouse model of glucose 6-phosphate dehydrogenase deficiency for in vivo assessment of hemolytic toxicity.

Rochford R, Ohrt C, Baresel PC, Campo B, Sampath A, Magill AJ, Tekwani BL, Walker LA.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17486-91. doi: 10.1073/pnas.1310402110. Epub 2013 Oct 7.

14.

Purnomo Projodipuro (April 11, 1934-May 10, 2013).

Baird JK, Elyazar I, Basri H, Chand K, Hoffman SL, Palmieri JR, Richie TL, Franke-Villasante E, Fryauff DJ, Ohrt C, Punjabi N, Maguire JD, Dennis DT, Sutanto I, Andersen E, Sismadi P.

Am J Trop Med Hyg. 2013 Aug;89(2):202-204. doi: 10.4269/ajtmh.13-0284. No abstract available. Erratum in: Am J Trop Med Hyg. 2013 Sep;89(3):608.

15.

The metabolism of primaquine to its active metabolite is dependent on CYP 2D6.

Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, Caridha D, Zeng Q, Reichard GA, Ockenhouse C, Bennett J, Walker LA, Ohrt C, Melendez V.

Malar J. 2013 Jun 20;12:212. doi: 10.1186/1475-2875-12-212.

16.

Haemoglobin dynamics in Papuan and non-Papuan adults in northeast Papua, Indonesia, with acute, uncomplicated vivax or falciparum malaria.

Taylor WR, Widjaja H, Basri H, Tjitra E, Ohrt C, Taufik T, Baso S, Hoffman SL, Richie TL.

Malar J. 2013 Jun 19;12:209. doi: 10.1186/1475-2875-12-209.

17.

Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects.

Miller AK, Harrell E, Ye L, Baptiste-Brown S, Kleim JP, Ohrt C, Duparc S, Möhrle JJ, Webster A, Stinnett S, Hughes A, Griffith S, Beelen AP.

Br J Clin Pharmacol. 2013 Dec;76(6):858-67. doi: 10.1111/bcp.12160.

18.

An in vivo drug screening model using glucose-6-phosphate dehydrogenase deficient mice to predict the hemolytic toxicity of 8-aminoquinolines.

Zhang P, Gao X, Ishida H, Amnuaysirikul J, Weina PJ, Grogl M, O'Neil MT, Li Q, Caridha D, Ohrt C, Hickman M, Magill AJ, Ray P.

Am J Trop Med Hyg. 2013 Jun;88(6):1138-45. doi: 10.4269/ajtmh.12-0682. Epub 2013 Mar 25.

19.

CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine.

Pybus BS, Sousa JC, Jin X, Ferguson JA, Christian RE, Barnhart R, Vuong C, Sciotti RJ, Reichard GA, Kozar MP, Walker LA, Ohrt C, Melendez V.

Malar J. 2012 Aug 2;11:259. doi: 10.1186/1475-2875-11-259.

20.

Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances.

Deye GA, Gettayacamin M, Hansukjariya P, Im-erbsin R, Sattabongkot J, Rothstein Y, Macareo L, Fracisco S, Bennett K, Magill AJ, Ohrt C.

Am J Trop Med Hyg. 2012 Jun;86(6):931-5. doi: 10.4269/ajtmh.2012.11-0552.

21.

Estimation of measurement uncertainties using virtual fringe projection technique.

Haskamp K, Kästner M, Ohrt C, Reithmeier E.

Appl Opt. 2012 Apr 1;51(10):1516-20. doi: 10.1364/AO.51.001516.

PMID:
22505069
22.

Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin.

Perić M, Fajdetić A, Rupčić R, Alihodžić S, Ziher D, Bukvić Krajačić M, Smith KS, Ivezić-Schönfeld Z, Padovan J, Landek G, Jelić D, Hutinec A, Mesić M, Ager A, Ellis WY, Milhous WK, Ohrt C, Spaventi R.

J Med Chem. 2012 Feb 9;55(3):1389-401. doi: 10.1021/jm201615t. Epub 2012 Jan 25.

PMID:
22148880
23.

Review: Improving the therapeutic index of 8-aminoquinolines by the use of drug combinations: review of the literature and proposal for future investigations.

Myint HY, Berman J, Walker L, Pybus B, Melendez V, Baird JK, Ohrt C.

Am J Trop Med Hyg. 2011 Dec;85(6):1010-4. doi: 10.4269/ajtmh.2011.11-0498. Review.

24.

Absolute bioavailability of cis-mirincamycin and trans-mirincamycin in healthy rhesus monkeys and ex vivo antimalarial activity against Plasmodium falciparum.

Khemawoot P, Saunders D, Rasameesoraj M, Melendez V, Imerbsin R, Ohrt C, Fracisco S, Teja-Isavadharm P.

Antimicrob Agents Chemother. 2011 Dec;55(12):5881-6. doi: 10.1128/AAC.01619-10. Epub 2011 Sep 26.

25.

Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta).

Dow GS, Gettayacamin M, Hansukjariya P, Imerbsin R, Komcharoen S, Sattabongkot J, Kyle D, Milhous W, Cozens S, Kenworthy D, Miller A, Veazey J, Ohrt C.

Malar J. 2011 Jul 29;10:212. doi: 10.1186/1475-2875-10-212.

26.

Plasmodium falciparum infection during suppressive prophylaxis with mefloquine does not induce an antibody response to merozoite surface protein-1(42).

Moon JE, Deye GA, Miller L, Fracisco S, Miller RS, Tosh D, Cummings JF, Ohrt C, Magill AJ.

Am J Trop Med Hyg. 2011 May;84(5):825-9. doi: 10.4269/ajtmh.2011.10-0699.

27.

Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides.

Bukvić Krajačić M, Perić M, Smith KS, Schönfeld ZI, Žiher D, Fajdetić A, Kujundžić N, Schönfeld W, Landek G, Padovan J, Jelić D, Ager A, Milhous WK, Ellis W, Spaventi R, Ohrt C.

J Med Chem. 2011 May 26;54(10):3595-605. doi: 10.1021/jm2001585. Epub 2011 May 4.

PMID:
21476508
28.

An automated, polymer-assisted strategy for the preparation of urea and thiourea derivatives of 15-membered azalides as potential antimalarial chemotherapeutics.

Hutinec A, Rupčić R, Ziher D, Smith KS, Milhous W, Ellis W, Ohrt C, Schönfeld ZI.

Bioorg Med Chem. 2011 Mar 1;19(5):1692-701. doi: 10.1016/j.bmc.2011.01.030. Epub 2011 Jan 22.

PMID:
21316974
29.

Antimalarial activity of novel 5-aryl-8-aminoquinoline derivatives.

Shiraki H, Kozar MP, Melendez V, Hudson TH, Ohrt C, Magill AJ, Lin AJ.

J Med Chem. 2011 Jan 13;54(1):131-42. doi: 10.1021/jm100911f. Epub 2010 Dec 8.

PMID:
21141892
30.

Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.

Nasveld PE, Edstein MD, Reid M, Brennan L, Harris IE, Kitchener SJ, Leggat PA, Pickford P, Kerr C, Ohrt C, Prescott W; Tafenoquine Study Team.

Antimicrob Agents Chemother. 2010 Feb;54(2):792-8. doi: 10.1128/AAC.00354-09. Epub 2009 Dec 7.

31.

A randomized, double-blind, safety and tolerability study to assess the ophthalmic and renal effects of tafenoquine 200 mg weekly versus placebo for 6 months in healthy volunteers.

Leary KJ, Riel MA, Roy MJ, Cantilena LR, Bi D, Brater DC, van de Pol C, Pruett K, Kerr C, Veazey JM Jr, Beboso R, Ohrt C.

Am J Trop Med Hyg. 2009 Aug;81(2):356-62.

PMID:
19635898
32.
33.

Changes in the total leukocyte and platelet counts in Papuan and non Papuan adults from northeast Papua infected with acute Plasmodium vivax or uncomplicated Plasmodium falciparum malaria.

Taylor WR, Widjaja H, Basri H, Ohrt C, Taufik T, Tjitra E, Baso S, Fryauff D, Hoffman SL, Richie TL.

Malar J. 2008 Dec 18;7:259. doi: 10.1186/1475-2875-7-259.

34.

Novel efficient design of Y-splitter for surface plasmon polariton applications.

Passinger S, Seidel A, Ohrt C, Reinhardt C, Stepanov A, Kiyan R, Chichkov B.

Opt Express. 2008 Sep 15;16(19):14369-79.

PMID:
18794972
35.

Pilot assessment of the sensitivity of the malaria thin film.

Ohrt C, O'Meara WP, Remich S, McEvoy P, Ogutu B, Mtalib R, Odera JS.

Malar J. 2008 Jan 28;7:22. doi: 10.1186/1475-2875-7-22.

36.

Establishing a malaria diagnostics centre of excellence in Kisumu, Kenya.

Ohrt C, Obare P, Nanakorn A, Adhiambo C, Awuondo K, O'Meara WP, Remich S, Martin K, Cook E, Chretien JP, Lucas C, Osoga J, McEvoy P, Owaga ML, Odera JS, Ogutu B.

Malar J. 2007 Jun 12;6:79.

37.

In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome.

Noedl H, Krudsood S, Leowattana W, Tangpukdee N, Thanachartwet W, Looareesuwan S, Miller RS, Fukuda M, Jongsakul K, Yingyuen K, Sriwichai S, Ohrt C, Knirsch C.

Antimicrob Agents Chemother. 2007 Feb;51(2):651-6. Epub 2006 Nov 20.

38.

Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodium falciparum malaria in adults: a randomized, phase 2 clinical trial in Thailand.

Noedl H, Krudsood S, Chalermratana K, Silachamroon U, Leowattana W, Tangpukdee N, Looareesuwan S, Miller RS, Fukuda M, Jongsakul K, Sriwichai S, Rowan J, Bhattacharyya H, Ohrt C, Knirsch C.

Clin Infect Dis. 2006 Nov 15;43(10):1264-71. Epub 2006 Oct 12.

PMID:
17051490
39.

Systematic comparison of two methods to measure parasite density from malaria blood smears.

Prudhomme O'Meara W, Remich S, Ogutu B, Lucas M, Mtalib R, Obare P, Oloo F, Onoka C, Osoga J, Ohrt C, McKenzie FE.

Parasitol Res. 2006 Sep;99(4):500-4. Epub 2006 Mar 30.

40.

Effective treatment of uncomplicated Plasmodium falciparum malaria with azithromycin-quinine combinations: a randomized, dose-ranging study.

Miller RS, Wongsrichanalai C, Buathong N, McDaniel P, Walsh DS, Knirsch C, Ohrt C.

Am J Trop Med Hyg. 2006 Mar;74(3):401-6.

PMID:
16525097
41.

Tolerability of azithromycin as malaria prophylaxis in adults in northeast papua, indonesia.

Taylor WR, Richie TL, Fryauff DJ, Ohrt C, Picarima H, Tang D, Murphy GS, Widjaja H, Braitman D, Tjitra E, Ganjar A, Jones TR, Basri H, Berman J.

Antimicrob Agents Chemother. 2003 Jul;47(7):2199-203.

42.

Assessing the Parasight-F test in northeastern Papua, Indonesia, an area of mixed Plasmodium falciparum and Plasmodium vivax transmission.

Taylor WR, Widjaja H, Basri H, Fryauff DJ, Ohrt C, Taufik, Tjitra E, Hoffman SL, Baso S, Richie TL.

Am J Trop Med Hyg. 2002 Jun;66(6):649-52.

PMID:
12224568
43.

Impact of microscopy error on estimates of protective efficacy in malaria-prevention trials.

Ohrt C, Purnomo, Sutamihardja MA, Tang D, Kain KC.

J Infect Dis. 2002 Aug 15;186(4):540-6. Epub 2002 Aug 2.

PMID:
12195382
44.

Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro.

Ohrt C, Willingmyre GD, Lee P, Knirsch C, Milhous W.

Antimicrob Agents Chemother. 2002 Aug;46(8):2518-24.

45.

A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria.

Shanks GD, Oloo AJ, Aleman GM, Ohrt C, Klotz FW, Braitman D, Horton J, Brueckner R.

Clin Infect Dis. 2001 Dec 15;33(12):1968-74. Epub 2001 Nov 7.

PMID:
11700577
46.

Chloroquine/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya, Indonesia.

Taylor WR, Widjaja H, Richie TL, Basri H, Ohrt C, Tjitra, Taufik E, Jones TR, Kain KC, Hoffman SL.

Am J Trop Med Hyg. 2001 May-Jun;64(5-6):223-8.

PMID:
11463107
47.

Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.

Abernethy DR, Wesche DL, Barbey JT, Ohrt C, Mohanty S, Pezzullo JC, Schuster BG.

Br J Clin Pharmacol. 2001 Mar;51(3):231-7.

48.

Determination of failure of treatment of plasmodium falciparum infection by using polymerase chain reaction single-strand conformational polymorphism fingerprinting.

Ohrt C, Mirabelli-Primdahl L, Looareesuwan S, Wilairatana P, Walsh D, Kain KC.

Clin Infect Dis. 1999 Apr;28(4):847-52.

PMID:
10825049
49.

Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia.

Taylor WR, Richie TL, Fryauff DJ, Picarima H, Ohrt C, Tang D, Braitman D, Murphy GS, Widjaja H, Tjitra E, Ganjar A, Jones TR, Basri H, Berman J.

Clin Infect Dis. 1999 Jan;28(1):74-81.

PMID:
10028075
50.

Supplemental Content

Support Center